Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
4(100.0%)
4Total
N/A(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07369180Not ApplicableEnrolling By Invitation

NQ Square TMS for MDD 1Dx3S Adults Multi-site Sham-controlled Protocol

Role: lead

NCT06772987Not ApplicableCompleted

NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient

Role: lead

NCT03986658Not ApplicableUnknown

Linear Asymmetric rTMS in Adolescent Treatment-Resistant Depression: Tolerability of Treatment Durations Ranging From Ten Days to One Day

Role: lead

NCT02667041Not ApplicableCompleted

NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial

Role: collaborator

All 4 trials loaded